Actavis
Actavis[edit]
Actavis plc was a global pharmaceutical company that, after a series of mergers, became a part of the current company Allergan plc.
Overview[edit]
Originally based in Iceland, Actavis grew rapidly through both organic growth and acquisitions, eventually becoming one of the largest generic pharmaceutical companies in the world.
History[edit]
- 1956: Actavis was founded in Iceland as Pharmaco.
- 1999: The company was renamed Actavis following a merger.
- 2000s: Actavis experienced rapid growth and expansion, completing numerous acquisitions globally.
- 2015: Actavis completed the acquisition of Allergan, Inc., a transformative deal. Post-acquisition, the combined company adopted the name Allergan plc.
Notable Acquisitions[edit]
- Warner Chilcott: In 2013, Actavis acquired the specialty pharmaceutical company, enhancing its branded drug portfolio.
- Forest Laboratories: Acquired in 2014, this deal significantly expanded Actavis' branded drug business.
Key Products[edit]
Actavis had a vast product range that covered various therapeutic areas. Some of the most notable include:
- Generic formulations of blockbuster drugs.
- Specialty brand pharmaceuticals in areas such as women’s health, gastroenterology, and dermatology.
Facilities[edit]
Actavis had manufacturing, R&D, and commercial operations worldwide. Its facilities adhered to global quality standards and catered to both domestic and international markets.
Corporate Culture[edit]
Actavis was known for its dynamic culture, emphasizing innovation, growth, and a commitment to delivering high-quality pharmaceuticals to patients globally.
Controversies[edit]
The rapid growth of Actavis and its aggressive acquisition strategy did lead to certain criticisms, especially around issues of drug pricing and antitrust concerns.
See Also[edit]
References[edit]
- [1] "Actavis: Company History". Actavis Corporate Archive.
- [2] "Actavis and the Landscape of Generic Pharmaceuticals". Pharmaceutical Journal.
- [3] "Actavis Completes Allergan Acquisition". Financial Times.